Biotech

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde

Biotech

Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

By Rebecca Robbins

Biotech

Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict

By Kate Sheridan

The Readout LOUD

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

Veritas, genetics company founded by George Church, suspends U.S. operations

By Kate Sheridan

Biotech

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

By Rebecca Robbins and Matthew Herper

Biotech

Sage’s new antidepressant faces major setback in new study

By Matthew Herper and Adam Feuerstein

Biotech

Eli Lilly places the team from a startup it bought in January in charge of its cancer research

By Matthew Herper

Biotech

Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial

By Adam Feuerstein

Biotech

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

By Rebecca Robbins

STAT Summit

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

By STAT staff

Biotech

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

By Nicholas Florko

Biotech

Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

By Kate Sheridan

Biotech

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

By Kate Sheridan

Biotech

Global Blood secures FDA approval for new pill to treat sickle cell disease

By Adam Feuerstein

Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Biotech

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

By Adam Feuerstein

Biotech

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

By Kate Sheridan

Biotech

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

By Damian Garde

Biotech

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

By Kate Sheridan

Biotech

First CRISPR treatment for blood diseases shows early benefits in two patients

By Sharon Begley and Adam Feuerstein

Biotech

Novo Nordisk’s parent company to launch research incubator in Boston

By Kate Sheridan

Biotech

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

By Chris Morrison

Biotech

Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth

By Kate Sheridan

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

Constellation’s blood cancer drug shows strong results, but skepticism may not fade

Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

Veritas, genetics company founded by George Church, suspends U.S. operations

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

Sage’s new antidepressant faces major setback in new study

Eli Lilly places the team from a startup it bought in January in charge of its cancer research

Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

Global Blood secures FDA approval for new pill to treat sickle cell disease

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

First CRISPR treatment for blood diseases shows early benefits in two patients

Novo Nordisk’s parent company to launch research incubator in Boston

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth